{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-002582","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2023-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.593788+00:00","generated_at":"2026-06-20T08:12:18.891222+00:00","sec_items":["3.02","5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Biostage CEO David Green reduces cash salary to $35,568; receives $264K stock option","bullets":["CEO David Green reduced annual base salary from $300,000 to $35,568 (minimum required by law).","Received nonqualified stock option valued at $264,432 (Black-Scholes) for the salary reduction difference.","Option vests monthly over 12 months; exercise price equals closing price on grant date (Jan 25, 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-002582","json":"https://secwatch.observer/filing/0001493152-23-002582.json","markdown":"https://secwatch.observer/filing/0001493152-23-002582.md","text":"https://secwatch.observer/filing/0001493152-23-002582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223002582/0001493152-23-002582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223002582/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T08:12:18.891222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}